EMILEE HOOVER: Open Payments
NPI 1427702729 · LEE'S SUMMIT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,353 in 52 payments from 16 companies in 2025. Trend: 2023 $290 · 2024 $678 · 2025 $1,353
Food & beverage: $1,269Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $382 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $184 |
| Janssen Biotech, Inc. | 5 | $177 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $130 |
| Lilly USA, LLC | 5 | $120 |
| Madrigal Pharmaceuticals | 3 | $70 |
| Ipsen Biopharmaceuticals, Inc | 3 | $63 |
| Celltrion USA Inc. | 3 | $54 |
| Ardelyx, Inc. | 2 | $39 |
| QOL Medical, LLC | 1 | $32 |
Products named: TREMFYA, SKYRIZI, XIFAXAN, RINVOQ, ENTYVIO, OMVOH, REZDIFFRA, IQIRVO.
Industry payments across MO — which companies pay providers there.
